A Randomized Phase 1 of of MZE001 in Healthy Volunteers

Healthy Clinical Trial

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of MZE001 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05249621
• Other study ID #: MZE001-01
• Status: Completed
• Phase: Phase 1
• Start date: February 7, 2022
• Est. completion date: December 21, 2022

Study information

• Verified date: February 2023
• Source: Maze Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single (SAD) / multiple (MAD) ascending dose and food effect study.

Description:

Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered MZE001 in healthy subjects, in fasted and fed states. Each SAD and MAD cohort will enroll 8 subjects randomized 6 active: 2 placebo to receive single or multiple doses of MZE001.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 121
• Est. completion date: December 21, 2022
• Est. primary completion date: December 21, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Male and female subjects, ages 18 - 55 years, inclusive;

2. Must provide written informed consent prior to any study assessments and be willing and able to comply with all study procedures;

3. Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive;

4. Healthy as determined by the Investigator based on pre-study medical history, physical examination, and baseline safety laboratory studies.

5. Able to complete exercise treadmill test with no cardiac abnormalities detected

6. Females of childbearing potential who are sexually active with a non-sterilized partner must use a highly effective method of contraception during study participation and for 30 days after last administration of study drug.

7. Males of childbearing potential must use a highly effective method of birth control during study participation and for 90 days after last administration of study drug.

Exclusion Criteria:

1. Any concurrent condition that in the opinion of the Investigator would interfere with the evaluation of the investigational product or lead to increased risk of harm;

2. Any history of coronary artery disease or cardiovascular disease;

3. History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs;

4. History of cancer within past 5 years, with the exception of non-melanoma skin cancer and treated / excised melanoma;

5. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to the Screening visit;

6. Fridericia's corrected QT (QTcF) > 450 ms for male participants and > 470 ms for female participants or history of QT interval prolongation;

7. History or presence of an abnormal ECG that is clinically significant in the Investigator's opinion

8. Resting seated blood pressure < 90/40 mmHg or > 140/90 mmHg

9. Resting seated heart rate < 45 bpm or > 99 bpm

10. Poor peripheral venous access;

11. Have a history of drug hypersensitivity or anaphylaxis;

12. Current smoker or recent history of smoking within the last 3 months prior to the Screening visit;

13. Have a history of alcoholism or drug abuse or positive drug screen

14. Have used any prescription or non-prescription medicines or have been administered a vaccine within 14 days of admission,

15. Have received any investigational drug within 30 days or < 5 half-lives, whichever is longer, prior to the Screening visit;

16. Have donated or received any blood or blood products within the 3 months prior to the Screening visit.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• MZE001
Small molecule inhibitor of muscle glycogen synthase
• Placebo
Product containing excipients with no active ingredients

Locations

Country	Name	City	State
United States	Orange County Research Center	Tustin	California

Sponsors (1)

Lead Sponsor	Collaborator
Maze Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events as a measure of safety and tolerability of MZE001	Occurrence of adverse events, serious adverse events, adverse events of special interest	14 days
Secondary	Maximum concentration following multiple doses of MZE001	PK	14 days
Secondary	AUC following multiple doses of MZE001	PK	14 days
Secondary	Accumulation ratio following multiple doses of MZE001	PK	14 days